Today marks the beginning of the end for compounded GLP-1s writ-large.

Novo dragged its feet, but Hims/Hers launching its illegal oral Wegovy knock off was the tipping point for it to take serious legal action to protect its IP from open and blatant theft.

Other telehealth players are likely already calling their existing patients trying to unload compounded inventory before they will be forced to pull them off the market.

Telehealth has more to gain working WITH drug makers to create more value for patients as opposed to working against them. The smart ones will realize that and follow suit. The others will fall by the wayside.